Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
Dec 15, 2025
01:53
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.
Pharmaceutical Executive